Guo Chenghu, Liu Xiaoling, Mei Zeyuan, Chang Meiling, Li Jiaqi, Wang Baiqiang, Ji Wei, Zhang Meng, Zhang Mei, Zhang Cheng, An Guipeng
State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Department of Ultrasonography, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, 250014 Jinan, China.
Theranostics. 2025 Mar 18;15(10):4398-4415. doi: 10.7150/thno.109182. eCollection 2025.
Calcific aortic valve disease (CAVD) is a progressive disorder characterized by aortic valve (AV) calcification and fibrosis. Despite advances in our understanding of CAVD pathogenesis, no drug has proven effective in preventing AV calcification. The aim of this study was to identify the key pathogenic genes in CAVD and elucidate mechanisms that may guide development of new targeted therapies. A CAVD model was established in ApoE mice by administering a high-cholesterol diet for 24 weeks. An adeno-associated virus was used to induce alpha-1-microglobulin/bikunin precursor (AMBP) overexpression. RNA sequencing, quantitative real-time polymerase chain reaction, western blotting, immunofluorescence, histopathology, and echocardiography were performed to assess AV function. The mechanism of interaction between AMBP and four-and-a-half LIM domain protein 3 (FHL3) was explored using bioinformatics analyses, co-immunoprecipitation, and AlphaFold3-based simulations of crystal structures. RNA sequencing identified AMBP as a key regulator of CAVD. AMBP was increased in calcified AV from CAVD patients and high cholesterol diet (HCD)-induced ApoE mice. , AMBP overexpression significantly reduced HCD-induced AV calcification and fibrosis. , AMBP knockdown elevated osteogenic markers, RUNX2 and OSTERIX, and promoted calcium deposition in valvular interstitial cells induced by osteogenic medium (OM), whereas AMBP overexpression reversed these effects. Mechanistically, AMBP inhibited OM-induced phosphorylation of ERK1/2 (P-ERK1/2) and JNK (P-JNK) by competitively binding to the zinc finger domain of FHL3. This interaction disrupted the protective role of FHL3 in preventing ubiquitin-proteasome-mediated degradation of P-ERK1/2 and P-JNK. P-ERK1/2 and P-JNK inhibitors and agonists confirmed that the protective effects of AMBP against CAVD were mediated via these pathways and . AMBP protects valvular interstitial cells from osteoblastic differentiation and calcium deposit accumulation, thereby alleviating AV calcification. This study sheds additional light on the pathogenesis of CAVD and potential new therapeutic approaches.
钙化性主动脉瓣疾病(CAVD)是一种以主动脉瓣(AV)钙化和纤维化为特征的进行性疾病。尽管我们对CAVD发病机制的理解有所进展,但尚无药物被证明能有效预防AV钙化。本研究的目的是确定CAVD中的关键致病基因,并阐明可能指导新的靶向治疗药物开发的机制。通过给ApoE小鼠喂食高胆固醇饮食24周建立CAVD模型。使用腺相关病毒诱导α-1-微球蛋白/比库宁前体(AMBP)过表达。进行RNA测序、定量实时聚合酶链反应、蛋白质免疫印迹、免疫荧光、组织病理学和超声心动图以评估AV功能。使用生物信息学分析、免疫共沉淀和基于AlphaFold3的晶体结构模拟来探索AMBP与四半LIM结构域蛋白3(FHL3)之间的相互作用机制。RNA测序确定AMBP是CAVD的关键调节因子。在CAVD患者的钙化AV和高胆固醇饮食(HCD)诱导的ApoE小鼠中,AMBP水平升高。AMBP过表达显著减少HCD诱导的AV钙化和纤维化。AMBP敲低提高了成骨标志物RUNX2和OSTERIX,并促进了成骨培养基(OM)诱导的瓣膜间质细胞中的钙沉积,而AMBP过表达则逆转了这些作用。机制上,AMBP通过竞争性结合FHL3的锌指结构域抑制OM诱导的ERK1/2(P-ERK1/2)和JNK(P-JNK)磷酸化。这种相互作用破坏了FHL3在防止泛素-蛋白酶体介导的P-ERK1/2和P-JNK降解中的保护作用。P-ERK1/2和P-JNK抑制剂及激动剂证实,AMBP对CAVD的保护作用是通过这些途径介导的。AMBP保护瓣膜间质细胞免于成骨细胞分化和钙沉积积累,从而减轻AV钙化。本研究为CAVD的发病机制和潜在的新治疗方法提供了更多线索。